Coagulation disorders and bleeding in liver disease: future directions.
Much has changed since the characterization of the wide spectrum of abnormalities in the coagulation system in patients who have acute and chronic liver disease. With inherent limitations of conventional laboratory measures of coagulation in liver disease, it is now incumbent on us to explore how best to apply (or withhold) specific agents in specific situations. This will clearly require well focused translational research to understand and bring into sharp focus the various problems present, from dysfibrinogen to endogenous heparinoids, to uremia, to hyperfibrinolysis and even to unrecognized hypercoagulable conditions. The challenge lies ahead.
Caldwell
Stephen H
SH
GI/Hepatology Division, Digestive Health Center of Excellence, University of Virginia Medical Center, Box 800708, Charlottesville, VA 22908 0708, USA. Electronic address: shc5c@virginia.edu.
Sanyal
Arun J
AJ
Division of GI/Hepatology and Nutrition, Department of Internal Medicine, VCU School of Medicine, MCV Box 980341, Richmond, VA 23298 0341, USA.
D000925:Anticoagulants / Q000627:therapeutic use; D001778:Blood Coagulation Disorders / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology*; D006470:Hemorrhage / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology*; D006801:Humans; D019934:International Normalized Ratio; D008103:Liver Cirrhosis / Q000097:blood* / Q000150:complications; D018570:Risk Assessment / Q000639:trends
D000925:Anticoagulants